GRPR antagonists, such as RM2, labeled with a therapeutic radioisotope (e.g., Lutetium-177 or Yittrium-90) could be used to treat BC patients while using Ga-68 labeled RM2 as a diagnostic companion to select potential candidates for this therapy and monitoring treatment response. This evidence concerns the gene GRPR and breast cancer.